A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.

The development of antisense and gene therapy has focused mainly on improving methods for oligonucleotide and gene delivery into cells. In the present work, we describe a potent new strategy for oligonucleotide delivery based on the use of a short peptide vector, termed MPG (27 residues), which contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain derived from the nuclear localization sequence of SV40 T-antigen. The formation of peptide vector/oligonucleotide complexes was investigated by measuring changes in intrinsic tryptophan fluorescence of peptide and of mansyl-labelled oligonucleotides. MPG exhibits relatively high affinity for both single- and double-stranded DNA in a nanomolar range. Based on both intrinsic and extrinsic fluorescence titrations, it appears that the main binding between MPG and oligonucleotides occurs through electrostatic interactions, which involve the basic-residues of the peptide vector. Further peptide/peptide interactions also occur, leading to a higher MPG/oligonucleotide ratio (in the region of 20/1), which suggests that oligonucleotides are most likely coated with several molecules of MPG. Premixed complexes of peptide vector with single or double stranded oligonucleotides are delivered into cultured mammalian cells in less than 1 h with relatively high efficiency (90%). This new strategy of oligonucleotide delivery into cultured cells based on a peptide vector offers several advantages compared to other commonly used approaches of delivery including efficiency, stability and absence of cytotoxicity. The interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and crossing of the plasma membrane. The mechanism of cell delivery of oligonucleotides by MPG does not follow the endosomal pathway, which explains the rapid and efficient delivery of oligonucleotides in the nucleus. As such, we propose this peptide vector as a powerful tool for potential development in gene and antisense therapy.

[1]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[2]  K Mechtler,et al.  The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. , 1994, The Journal of biological chemistry.

[3]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[4]  S. Agrawal,et al.  Antisense oligonucleotides: towards clinical trials. , 1996, Trends in biotechnology.

[5]  J. Reinstein,et al.  Interaction of fluorescently labeled dideoxynucleotides with HIV-1 reverse transcriptase. , 1991, Biochemistry.

[6]  Anne Fernandez,et al.  Cyclin a is required for the onset of DNA replication in mammalian fibroblasts , 1991, Cell.

[7]  R. Goody,et al.  Kinetics of interaction of HIV reverse transcriptase with primer/template. , 1993, Biochemistry.

[8]  C. Granier,et al.  Disulfide linkage to polyacrylic resin for automated Fmoc peptide synthesis. Immunochemical applications of peptide resins and mercaptoamide peptides. , 2009, International journal of peptide and protein research.

[9]  J. Bonifacino,et al.  Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues. , 1996, Virology.

[10]  G. Deléage,et al.  Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. , 1995, Journal of molecular biology.

[11]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[12]  C Dingwall,et al.  The nuclear membrane. , 1992, Science.

[13]  D. Baltimore Intracellular immunization , 1988, Nature.

[14]  W. Richardson,et al.  Sequence requirements for nuclear location of simian virus 40 large-T antigen , 1984, Nature.

[15]  N. Lemoine,et al.  Strategies for targeted gene therapy. , 1996, Trends in genetics : TIG.

[16]  R. Wagner Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[17]  J. Ruysschaert,et al.  Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer , 1996, Journal of virology.

[18]  V. Georgiev Virology , 1955, Nature.

[19]  W. Gallaher,et al.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus , 1987, Cell.

[20]  Olivier Danos,et al.  Nucleotide sequence of the AIDS virus, LAV , 1985, Cell.